480 Arsenal Street
About Syros PharmaceuticalsWe are a therapeutics company passionately committed to applying our scientific leadership in the emerging field of gene control to transform the lives of patients with cancer and other diseases.
Founded by world-leading experts in gene regulation, and led by a seasoned management team, Syros is focused on developing new medicines that control genes that cause disease. Central to our approach is a proprietary drug development platform of integrated gene control assay technologies, computational biology, chemistry, and deep biologic insights that gives us an unprecedented understanding of and control over gene regulation. Our pioneering research and drug development capabilities provide us with the distinctive ability to identify new, important disease and patient-targeted gene control medicines.
118 articles with Syros Pharmaceuticals
Syros Reports Fourth Quarter and Full Year 2017 Financial Results and Highlights Recent Accomplishments and Anticipated Milestones
Announced global collaboration with Incyte to use proprietary gene control platform to identify novel therapeutic targets in myeloproliferative neoplasms.
Mr. Ferra brings significant financial, strategic and leadership experience in the biotechnology industry.
Syros Announces Closing of Public Offering and Full Exercise of Option to Purchase Additional Shares
Syros today announced the closing of its previously announced underwritten public offering of common stock, including the exercise in full by the underwriters of their option to purchase an additional 628,272 shares at the public offering price of $9.55 per share.
Syros announced that it is offering to sell, subject to market and other conditions, $40.0 million of its common stock in an underwritten public offering.
Syros announced that it has priced an underwritten public offering of 4,188,481 shares of common stock at a price to the public of $9.55 per share, before underwriting discounts and commissions, which would result in aggregate gross proceeds of approximately $40.0 million.
A look at six biopharma companies that may have major stock catalysts this year.
Syros Announces Issuance of U.S. Patents Covering Methods for Stratifying Patients for Treatment with SY-1425, Its First-in-Class Selective RARα Agonist
Syros announced that the U.S. Patent and Trademark Office has issued two patents covering methods for stratifying patients with acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS) for treatment with SY-1425 (tamibarotene), the Company’s first-in-class selective retinoic acid receptor alpha (RARα) agonist.
In a presentation at the 36th Annual J.P. Morgan Healthcare Conference on Thursday, January 11, 2018, at 10:30 a.m. PST.
Incyte and Syros Announce Global Target Discovery and Validation Collaboration Focused on Myeloproliferative Neoplasms
Under the agreement, Syros will use its proprietary gene control platform to identify novel therapeutic targets with a focus in myeloproliferative neoplasms (MPNs), and Incyte will receive options to obtain exclusive worldwide rights to intellectual property resulting from the collaboration for up to seven validated targets
Syros Announces Clinical Supply Agreement With Janssen to Evaluate SY-1425, Its First-in-Class Selective RARα Agonist, in Combination with Daratumumab in Genomically Defined AML and MDS Patients
Under the agreement, Janssen will supply daratumumab for a recently added combination dosing cohort in Syros’ ongoing Phase 2 clinical trial of SY-1425, a first-in-class selective retinoic acid receptor alpha (RARα) agonist, in genomically defined subsets of patients with acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS).
Investors are not happy with interim Phase II data presented by Syros.
Syros Announces New Preclinical Data on SY-1365, Its First-in-Class Selective CDK7 Inhibitor, Pointing to a Potential Biomarker of Response and Combination Approach
Syros today announced that new preclinical data on SY-1365, its first-in-class selective cyclin-dependent kinase 7 (CDK7) inhibitor currently in a Phase 1 clinical trial in advanced solid tumors, show anti-tumor activity in in vitro and in vivo models of blood cancers.
Syros Presents New Preclinical Data on SY-1365, Its First-in-Class Selective CDK7 Inhibitor, and Discovery of Potential New Drug Targets in Triple Negative Breast Cancer at San Antonio Breast Cancer Symposium
Syros announced that new preclinical data on SY-1365, its first-in-class selective cyclin-dependent kinase 7 (CDK7) inhibitor currently in a Phase 1 clinical trial in advanced solid tumors, demonstrate anti-tumor activity across a broad panel of breast cancer cell lines and point to potential biomarkers predictive of response.
Dr. Springhorn will hold broad management responsibility for business development and strategic planning.
Syros Reports Third Quarter 2017 Financial Results and Highlights Accomplishments and Upcoming Milestones
Cash, cash equivalents and marketable securities as of September 30, 2017 were $81.9 million, compared with $83.6 million on December 31, 2016.
Syros to Present Initial Clinical Data from Ongoing Phase 2 Clinical Trial of SY-1425 and New Preclinical Data on SY-1365 at ASH Annual Meeting
Syros today announced that initial clinical data from the ongoing Phase 2 trial of SY-142 will be presented at the ASH Annual Meeting and Exposition taking place December 9-12 in Atlanta.
Syros Presents New Preclinical PK and PD Data for SY-1365, Its First-in-Class Selective CDK7 Inhibitor, at AACR-NCI-EORTC Conference
Syros Pharmaceuticals announced that new preclinical pharmacodynamic and pharmacokinetic data providing a rationale for the twice weekly dosing regimen currently being used in the ongoing Phase 1 clinical trial of SY-1365.
Syros’ Drug Discovery Research in Immuno-Oncology Highlighted in Oral Presentation at American College of Surgeons Clinical Congress
Syros today announced that it has identified alterations in regulatory regions of the genome in immune, tumor and stromal cells isolated from pancreatic cancer patient tumors, leading to the identification of new drug targets.
Syros Announces Oral Presentation Highlighting Its Drug Discovery Research in Immuno-Oncology at American College of Surgeons Clinical Congress
Syros Pharmaceuticals announced that the Company's drug discovery research in immuno-oncology will be highlighted in an oral presentation at the American College of Surgeons (ACS) 2017 Clinical Congress taking place October 22-26 in San Diego.
Syros To Present New Preclinical PK And PD Data On SY-1365, Its First-In-Class Selective CDK7 Inhibitor, At AACR-NCI-EORTC Conference
Syros Pharmaceuticals today announced that the Company will present preclinical pharmacokinetic (PK) and pharmacodynamic (PD) data on SY-1365 at the 2017 AACR-NCI-EORTC Molecular Targets and Cancer Therapeutics Conference taking place October 26-30 in Philadelphia.